Grants per year
- 25 - 50 out of 53 results
Search results
-
Finished
-
Prot #2215-CL-0101: A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
Astellas Pharma Global Development, Inc.
9/23/13 → 9/23/16
Project: Research project
-
-
Prot #EPZ-5676-12-001: A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients
Altman, J. K. (PD/PI)
7/22/13 → 7/22/16
Project: Research project
-
Prot #B1371003: A Phase 1B Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose ARA-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myel
Altman, J. K. (PD/PI)
ICON Clinical Research, LLC, Pfizer Inc.
10/17/12 → 10/17/18
Project: Research project
-
Prot #1315.1: A Phase I, Open, Cohort Dose Escalation Trial with BI 836858 in Patients with Refractory or Relapsed Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
Boehringer Ingelheim Pharmaceuticals, Inc.
10/12/12 → 10/12/18
Project: Research project
-
Prot# TTX404: A Phase 3, Multicenter, Randomized Study To Evaluate The Substitution Of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) For Standard Vincristine Sulfate Injection (VSI) In The Induction, Intensification, And Maintenance Phases Of Co
Altman, J. K. (PD/PI)
8/7/12 → 8/7/18
Project: Research project
-
Prot# NU MSK 11H01: Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients with Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Altman, J. K. (PD/PI), Frankfurt, O. (Co-PD/PI), Stein, B. L. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)
Memorial Sloan Kettering Cancer Center
6/15/12 → 6/15/18
Project: Research project
-
Prot# 2689-CL-2004: A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
Astellas Pharma Global Development, Inc.
5/30/12 → 5/30/18
Project: Research project
-
Prot# 2689-CL-0005: A Phase 1 Study of AC220 (ASP2689) in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
10/24/11 → 10/24/17
Project: Research project
-
Prot# C15003: An Open Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Altman, J. K. (PD/PI)
Millennium Pharmaceuticals, Inc.
6/17/11 → 6/17/14
Project: Research project
-
Prot# CYC682-12 (A2): A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Altman, J. K. (PD/PI)
6/15/11 → 6/15/17
Project: Research project
-
Prot# CLAVELA (CP4055-306): A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients with Late Stage Acute Myeloid Leukaemia
Altman, J. K. (PD/PI)
INC Research, LLC, Clavis Pharma ASA
3/16/11 → 3/16/14
Project: Research project
-
Prot#MEK111759: An Open-Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias
Altman, J. K. (PD/PI)
PRA Health Sciences, GlaxoSmithKline LLC
3/11/11 → 3/11/17
Project: Research project
-
Prot#AP24534-10-201: A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+Acute Lymphoblastic Leukemia
Altman, J. K. (PD/PI)
1/31/11 → 1/31/17
Project: Research project
-
Prot# CLBH589BUS58: Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients with Primary Myelofibrosis (PMF), Post-Essential Thrombocythemia (ET) Myelofibrosis and Post-Polycythemia Vera (PV) Myelofibrosis
Altman, J. K. (PD/PI)
PRA Health Sciences, Novartis Pharmaceuticals Corporation
11/12/09 → 1/1/11
Project: Research project
-
PROT# INCB 18424-351: A Randomized, Double-Blind, Placebo-Controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Essential Thrombocythemi
Altman, J. K. (PD/PI)
PPD Development, Incyte Corporation
11/3/09 → 10/2/18
Project: Research project
-
PROT# NU 08H9 - A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Altman, J. K. (PD/PI)
9/3/09 → 9/3/12
Project: Research project
-
PROT# C18477/6110/PM/US//NU 08H9: A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Altman, J. K. (PD/PI)
8/6/09 → 5/6/13
Project: Research project
-
Mnk Kinases as Therapeutic Targets in MDS and AML
Altman, J. K. (PD/PI)
Northwestern Memorial Foundation
1/1/09 → 12/31/09
Project: Research project
-
Mnk Kinases as Therapeutic Targets in MDS and AML
Altman, J. K. (PD/PI)
Northwestern Memorial Foundation
1/1/09 → 12/31/09
Project: Research project
-
Prot# H8K-MC-JZAJ: Phase 1 Study of LY573636-sodium in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
9/15/08 → 9/15/11
Project: Research project